Dry Age-Related Macular Degeneration | Decision Base | US | 2014

launch Related Market Assessment Reports

• Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Detailed, Expanded Analysis (US)

  November 2023

  CAR T-cell therapies, such as Gilead / Kite Pharma’s Yescarta and Janssen’s Carvykti, have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and patients…

• Attention-Deficit-Hyperactivity Disorder – Access & Reimbursement – Detailed, Expanded Analysis (US)

  November 2023

  Attention-deficit / hyperactivity disorder (ADHD) is a common childhood disorder that can persist through adolescence and into adulthood, although diagnosis and treatment initiation can occur at…

• Bipolar Disorder – Unmet Need – Detailed, Expanded Analysis (US/EU)

  October 2023

  Depressive episodes are more common than manic episodes in bipolar disorder (BPD) patients. Of note, BPD II is often characterized by a higher frequency of depressive episodes that last longer…

• Dry And Wet Age-Related Macular Degeneration – Geographic Focus-China – Dry And Wet Age-Related Macular Degeneration – China In-Depth (China)

  October 2023

  Age-related macular degeneration (AMD), which includes dry and wet AMD, is a leading cause of irreparable vision loss globally. In China, patients with wet AMD are typically treated with VEGF…

• Type 2 Diabetes – Access & Reimbursement – Detailed, Expanded Analysis (US)

  October 2023

  The sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are frequently prescribed for type 2 diabetes (T2D). These classes, along with glucose-…